Clinical trial NCT03077789: Prospective Study of the Diagnostic and Therapeutic Management of Congenital Glaucoma in France
Official title: Prospective Study of the Diagnostic and Therapeutic Management of Congenital Glaucoma in France
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Congenital Glaucoma
Keywords: visual acuity
prognosis epidemiology
Lead sponsor: University Hospital, Lille
Sponsor class: OTHER
First posted: 2017-03-13
Enrollment: 250
Sex: ALL
Maximum age (years): 4
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Evidence of a relationship between age at discovery of congenital glaucoma and visual acuity at 4 years of age.

The delay in diagnosis is a factor of poor visual acuity. Will justify the implementation of information programs with health and education professionals in order to improve the functional prognosis of patients with congenital glaucoma.

Detailed description: Prospective multicentre prospective cohort Enabling the identification and follow-up of an almost exhaustive population of incidents of congenital glaucoma in 23 ophthalmology centers in France Inclusion over 4 years Epidemiological data, all reports of consultation, medical and surgical procedures collected in an E-CRF.

Database for gene research related to congenital glaucoma to provide screening, genetic counseling and personalized care

Eligibility criteria: Inclusion Criteria:

* Boys or girls under the age of 4, without antecedent, French or resident in France, Suspected Glaucoma

Exclusion Criteria:

* Antecedent of surgery for glaucoma

Primary outcomes:
measure: Visual acuity by logarithmic scale of Sander-Zanlonghi
timeFrame: at 4 years of the child
Secondary outcomes:
measure: Intraocular pressure
timeFrame: at 4 years of the child
Other outcomes:
Locations:
city: Amiens
country: France
facility: Chu Amiens Picardie - Amiens 1
city: Amiens
country: France
facility: Chu Amiens Picardie
city: Angers
country: France
facility: Centre Hospitalier Regional D' Angers
city: Besançon
country: France
facility: CHRU Besançon
city: Bordeaux
country: France
facility: CHU Bordeaux
city: Clermont-Ferrand
country: France
facility: CHU de Clermont-Ferrand
city: Dijon
country: France
facility: CHU Dijon Bourgogne
city: Grenoble
country: France
facility: Chu de Grenoble Alpes
city: Lille
country: France
facility: CHRU, Hôpital Claude Huriez
city: Lyon
country: France
facility: Hopital Edouard Herriot - Hcl - Lyon 03
city: Marseille
country: France
facility: Aphm Hopital Nord
city: Montpellier
country: France
facility: CHRU de Montpellier
city: Montpellier
country: France
facility: CHU de Montpellier
city: Nantes
country: France
facility: Centre Hospitalier Universitaire
city: Nice
country: France
facility: Chu de Nice Hopital de L'Archet
city: Paris
country: France
facility: Fondation de Rothschild - Paris
city: Paris
country: France
facility: Hu Necker Enfants Malades Aphp - Paris 15
city: Reims
country: France
facility: Hopital Robert Debre Chu Reims
city: Rennes
country: France
facility: Chru Rennes Site Pontchaillou
city: Rouen
country: France
facility: Hopital Charles Nicolle Chu Rouen
city: Strasbourg
country: France
facility: Hopital Civil / Nouvel Hopital Civil - Strasbourg
city: Toulouse
country: France
facility: CHU de Toulouse
city: Tours
country: France
facility: CHRU de Tours
city: Tours
country: France
facility: Chu de Tours
Study officials:
affiliation: University Hospital, Lille
name: Jean-François ROULAND, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: